Gwo Xi Stem Cell Applied Technology Past Earnings Performance
Past criteria checks 0/6
Gwo Xi Stem Cell Applied Technology's earnings have been declining at an average annual rate of -5.7%, while the Biotechs industry saw earnings growing at 21.4% annually. Revenues have been declining at an average rate of 18.3% per year.
Key information
-5.7%
Earnings growth rate
-1.6%
EPS growth rate
| Biotechs Industry Growth | 12.2% |
| Revenue growth rate | -18.3% |
| Return on equity | -14.9% |
| Net Margin | -68.9% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Gwo Xi Stem Cell Applied Technology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 150 | -104 | 83 | 119 |
| 31 Mar 24 | 146 | -96 | 83 | 114 |
| 31 Dec 23 | 141 | -88 | 83 | 108 |
| 30 Sep 23 | 151 | -85 | 98 | 105 |
| 30 Jun 23 | 160 | -82 | 113 | 102 |
| 31 Mar 23 | 171 | -97 | 137 | 106 |
| 31 Dec 22 | 181 | -112 | 161 | 109 |
| 30 Sep 22 | 207 | -116 | 180 | 111 |
| 30 Jun 22 | 234 | -119 | 199 | 112 |
| 31 Mar 22 | 238 | -113 | 200 | 104 |
| 31 Dec 21 | 243 | -107 | 201 | 95 |
| 30 Sep 21 | 224 | -87 | 187 | 86 |
| 30 Jun 21 | 204 | -67 | 173 | 78 |
| 31 Mar 21 | 196 | -71 | 164 | 82 |
| 31 Dec 20 | 189 | -75 | 155 | 87 |
| 30 Jun 20 | 193 | -85 | 123 | 102 |
| 31 Mar 20 | 185 | -81 | 117 | 98 |
| 31 Dec 19 | 177 | -77 | 111 | 93 |
| 31 Dec 18 | 128 | -113 | 119 | 77 |
| 31 Dec 17 | 141 | -72 | 129 | 73 |
| 31 Dec 16 | 95 | -63 | 82 | 65 |
| 30 Jun 14 | 25 | -82 | 45 | 72 |
| 31 Mar 14 | 21 | -82 | 42 | 65 |
| 31 Dec 13 | 18 | -82 | 39 | 58 |
Quality Earnings: 6704 is currently unprofitable.
Growing Profit Margin: 6704 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6704 is unprofitable, and losses have increased over the past 5 years at a rate of 5.7% per year.
Accelerating Growth: Unable to compare 6704's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6704 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.8%).
Return on Equity
High ROE: 6704 has a negative Return on Equity (-14.89%), as it is currently unprofitable.